Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

AskBio licenses Selecta’s ImmTOR platform to develop AAV gene therapies for Pompe disease

Executive Summary

Following the success of proof-of-concept (POC) studies announced in August 2019, Asklepios BioPharmaceutical Inc. (AskBio) exercised its option to exclusively license development and commercialization rights to Selecta Biosciences Inc.’s immune tolerance platform, ImmTOR (antigen-specific biodegradable nanoparticle encapsulating the immunomodulator rapamycin), for use in adeno-associated virus (AAV)-based gene therapies for Pompe disease, a rare, inherited lysosomal storage disorder marked by neuromuscular, respiratory, and cardiac dysfunction.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal

Related Companies